癲癇藥物市場：依癲癇類型、藥物、給藥途徑、年齡層、通路、地區

癲癇藥物市場預計到2024年將達到103.1億美元，預計到2031年將達到147.7億美元，2024年至2031年的複合年成長率為5.3%。

圖：2024 年按地區分類的癲癇藥物市場佔有率(%)

癲癇是一種慢性非傳染性疾病，其特徵是反覆發作。癲癇發作是一種短暫的不自主運動，涉及身體的一部分或整個身體。其症狀包括腦部異常放電，導致癲癇發作。所有年齡層的人都可能受到影響，但在兒童和老年人中更為常見。雖然癲癇無法治療方法，但約 70% 的癲癇病例可透過藥物治療控制。全球癲癇藥物市場主要是由全球癲癇盛行率不斷上升所推動的。正在開發的新藥治療方案的進步也支持了市場的成長。

市場動態

全球癲癇藥物市場的成長主要是由全球癲癇盛行率不斷上升所推動的。根據世界衛生組織 (WHO) 估計，到 2022 年，全球將有超過 5,000 萬人受到癲癇的影響。市場也看到了各國醫療保健支出增加所帶來的機會。然而，由於重磅藥物的專利到期以及一些學名藥面臨的價格下降，市場成長可能會受到限制。此外，抗治療性癲癇新藥的市場開拓也是市場成長的機會。

本研究的主要特點

本報告對全球癲癇藥物市場進行了詳細分析，並列出了以2023年為基準年的預測期（2024-2031年）的市場規模和年複合成長率（CAGR%）。

它還揭示了各個細分市場的潛在商機，並為該市場說明了一系列有吸引力的投資提案。

它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要見解。

根據公司亮點、產品系列、主要亮點、績效和策略等參數對全球癲癇藥物市場的主要企業進行了分析。

調查涵蓋的主要企業包括輝瑞、住友製藥、諾華、雅培、葛蘭素史克、梯瓦製藥工業、賽諾菲、工業、Marinus Pharmaceuticals、Eisai、第一三共、Mylan NV、Dr. Reddy's Laboratories Ltd.、Sun Pharmaceutical Industries 、Neurelis, Inc.、Supernus Pharmaceuticals, Inc. 等。

從這份報告中獲得的見解將幫助負責人和公司經營團隊就未來的產品發布、升級、市場擴張和行銷策略做出明智的決策。

全球癲癇藥物市場報告針對該行業的各個相關人員，如投資者、供應商、產品製造商、經銷商、新進入者和財務分析師。

相關人員可以透過用於分析全球癲癇藥物市場的各種策略矩陣來促進他們的決策。

目錄

第1章 研究目的與前提

• 研究目的
• 先決條件
• 簡稱

第2章 市場展望

• 報告說明
  • 市場定義和範圍
• 執行摘要

第3章市場動態、法規及趨勢分析

• 市場動態
• 影響分析
• 主要亮點
• 監管場景
• 產品發布/核准
• PEST分析
• 波特分析
• 併購場景
• 流行病學
• 管道分析

第4章 癲癇藥物市場，依癲癇類型，2019-2031

• 2024年及2031年市場佔有率分析（%）
• 與前一年同期比較成長分析
• 細分市場趨勢
• 局部癲癇
  • 市場規模及預測、年成長與前一年同期比較
• 整體癲癇
  • 市場規模及預測、年成長與前一年同期比較
• 反射性癲癇
  • 市場規模及預測、年成長與前一年同期比較
• 其他（進行性性肌陣攣性癲癇等）
  • 市場規模及預測、年成長與前一年同期比較

第5章 癲癇藥物市場，依藥物分類，2019-2031

• 第一代
• 第二代
• 第三代

第6章 癲癇藥物市場，依給藥途徑，2019-2031

• 口服
• 可注射的
• 其他（鼻腔等）

第 7 章 癲癇藥物市場，依年齡層，2019-2031

• 兒科的
• 成人
• 老年人

第8章癲癇藥物市場，依分銷管道，2019-2031

• 醫院藥房
• 零售藥房
• 網路藥房

第 9 章 癲癇藥物市場，按地區，價值 2019-2031

• 北美洲
• 拉丁美洲
• 歐洲
• 亞太地區
• 中東
• 非洲

第10章競爭格局

• Pfizer Inc.
• Sumitomo Pharma Co., Ltd.
• Novartis AG
• Abbott
• GSK plc.
• Teva Pharmaceutical Industries Ltd.
• Sanofi
• Takeda Pharmaceutical Company Limited
• Marinus Pharmaceuticals, Inc
• Eisai Co., Ltd
• DAIICHI SANKYO COMPANY, LIMITED
• Mylan NV
• Reddy's Laboratories Ltd
• Sun Pharmaceutical Industries Ltd.
• Neurelis, Inc.
• Supernus Pharmaceuticals, Inc.

第11章分析師建議

• 命運之輪
• 分析師觀點
• 一致的機會圖

第12章參考文獻與調查方法

• 參考
• 調查方法
• 關於出版商

The epilepsy drugs market is estimated to be valued at USD 10.31 Bn in 2024 and is expected to reach USD 14.77 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 5.3% from 2024 to 2031.

Figure. Epilepsy Drugs Market Share (%), By Region, 2024

Epilepsy is a chronic non-communicable disease characterized by recurrent seizures, which are brief episodes of involuntary movement that may involve a part of the body or the entire body. Its symptoms include abnormal electrical discharges in the brain causing seizures. It affects people of all ages but is more common in children and older adults. There is no cure for epilepsy but seizures can be controlled in about 70% of cases with medication. The global epilepsy drugs market is primarily driven by the increasing prevalence of epilepsy worldwide. Advancements in the treatment options with new drugs in the pipeline also support the growth of this market.

Market Dynamics

Global epilepsy drugs market growth is primarily driven by increasing prevalence of epilepsy worldwide. In 2022, it was estimated that over 50 million people have epilepsy globally according to the World Health Organization. The market also witnesses opportunities due to the rising healthcare expenditures across various countries. However, the market growth can be restrained by the expiry of patents of blockbuster drugs and price erosion faced by some generic drugs. The development of novel drugs for treatment-resistant epilepsy also presents growth opportunities in the market.

Key Features of the Study:

This report provides in-depth analysis of the global epilepsy drugs market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global epilepsy drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Pfizer Inc., Sumitomo Pharma Co., Ltd., Novartis AG, Abbott, GSK plc., Teva Pharmaceutical Industries Ltd., Sanofi, Takeda Pharmaceutical Company Limited, Marinus Pharmaceuticals, Inc, Eisai Co., Ltd, DAIICHI SANKYO COMPANY, LIMITED, Mylan N.V., Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Ltd., Neurelis, Inc., and Supernus Pharmaceuticals, Inc.

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

Global epilepsy drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global epilepsy drugs market

Market Segmentation

• Type of Epilepsy Insights
  • Focal Epilepsy
  • Generalized Epilepsy
  • Reflex Epilepsy
  • Others (Progressive Myoclonic Epilepsy, etc.)
• Drugs Insights
  • 1st Generation
  • 2nd Generation
  • 3rd Generation
• Route of Administration Insights
  • Oral
  • Injectable
  • Others (Nasal, etc.)
• Age Group Insights
  • Pediatric
  • Adults
  • Geriatric
• Distribution Channel Insights
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Regional Insights
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
  • Pfizer Inc.
  • Sumitomo Pharma Co., Ltd.
  • Novartis AG
  • Abbott
  • GSK plc.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • Takeda Pharmaceutical Company Limited
  • Marinus Pharmaceuticals, Inc
  • Eisai Co., Ltd
  • DAIICHI SANKYO COMPANY, LIMITED
  • Mylan N.V.
  • Reddy's Laboratories Ltd
  • Sun Pharmaceutical Industries Ltd.
  • Neurelis, Inc.
  • Supernus Pharmaceuticals, Inc.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Epilepsy Drugs Market, By Type of Epilepsy
  • Epilepsy Drugs Market, By Drugs
  • Epilepsy Drugs Market, By Route of Administration
  • Epilepsy Drugs Market, By Age Group
  • Epilepsy Drugs Market, By Distribution Channel
  • Epilepsy Drugs Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario
• Epidemiology
• Pipeline Analysis

4. Epilepsy Drugs Market, Type of Epilepsy, 2019-2031, (USD Bn)

• Introduction
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Focal Epilepsy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Generalized Epilepsy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Reflex Epilepsy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Others (Progressive Myoclonic Epilepsy, etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

5. Epilepsy Drugs Market, By Drugs, 2019-2031, (USD Bn)

• Introduction
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• 1st Generation
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• 2nd Generation
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• 3rd Generation
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Epilepsy Drugs Market, By Route of Administration, 2019-2031, (USD Bn)

• Introduction
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Injectable
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Others (Nasal, etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Epilepsy Drugs Market, By Age Group, 2019-2031, (USD Bn)

• Introduction
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Pediatric
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Adults
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Geriatric
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Epilepsy Drugs Market, By Distribution Channel, 2019-2031, (USD Bn)

• Introduction
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

9. Epilepsy Drugs Market, By Region, 2019 - 2031, Value (USD Bn)

• Introduction
  • Market Share (%) Analysis, 2024,2027 & 2031, Value (USD Bn)
  • Market Y-o-Y Growth Analysis (%), 2020 - 2031, Value (USD Bn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, Type of Epilepsy, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Drugs, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
  • U.S.
  • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, Type of Epilepsy, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Drugs, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, Type of Epilepsy, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Drugs, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, Type of Epilepsy, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Drugs, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, Type of Epilepsy, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Drugs, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
  • GCC Countries
  • Israel
  • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, Type of Epilepsy, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Drugs, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Country/Region, 2019 - 2031, Value (USD Bn)
  • South Africa
  • North Africa
  • Central Africa

10. Competitive Landscape

• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Sumitomo Pharma Co., Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Novartis AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Abbott
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• GSK plc.
• Teva Pharmaceutical Industries Ltd.
• Sanofi
• Takeda Pharmaceutical Company Limited
• Marinus Pharmaceuticals, Inc
• Eisai Co., Ltd
• DAIICHI SANKYO COMPANY, LIMITED
• Mylan N.V.
• Reddy's Laboratories Ltd
• Sun Pharmaceutical Industries Ltd.
• Neurelis, Inc.
• Supernus Pharmaceuticals, Inc.

11. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

12. References and Research Methodology

• References
• Research Methodology
• About us